Trelagliptin Succinate for Type 2 Diabetes

                                                         Trelagliptin Succinate for Type 2 Diabetes

Trelagliptin succinate (SYR-472) is a selective, long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. An antidiabetic agent.

SYR-472 s the world's first weekly oral DPP 4 inhibitors, used in type 2 diabetes, this product is a weekly dipeptide base peptidase IV (DPP - 4) inhibitors, through selective, sustained suppression DPP - 4, control blood sugar levels. DPP - 4 is an enzyme that can cause intestinal insulin, glucagon like peptide 1 (glp-1) promote insulin and glucose dependence polypeptide (GIP) inactivation, and these two im down insulin plays an important role in regulating blood sugar. Inhibiting dd-4 can increase blood glucose levels dependent on insulin secretion, which can control blood glucose levels.
Generally, adults take orally SYR-472 100mg once a week.

Trelagliptin succinate is suitable for type 2 diabetes. It is a weekly dipeptidyl peptidase IV (DPP-4) inhibitor. It can control blood sugar levels by selectively 

and continuously inhibiting DPP-4. DPP-4 is an enzyme that can trigger the inactivation of incretin (glucagon-like peptide-1 (GLP-1) and glucose-dependent 

insulin-promoting polypeptide (GIP). It plays an important role in regulation. Inhibiting DPP-4 can increase blood glucose level-dependent insulin secretion, 

thereby controlling blood glucose levels.

Trelagliptin succinate CAS 1029877-94-8

Grade Standard   :Medicine Grade 
Purity:  99% 
Appearance : White Powder 
Packing : 100G/Bag 
Molecular Formula: C22H26FN5O6
Character： This product is soluble in dimethyl sulfoxide or water, slightly soluble in methanol, slightly soluble in absolute ethanol, very slightly soluble in acetonitrile, almost insoluble in methylene chloride 
Kind  :Pharmaceutical raw materials 
Industry:  medicine 
Area  :Antihypertensive and hypoglycemic drugs 
Related Products Troglitin Succinate Tablets